The plasma fractionation market focuses on processing human plasma to extract vital therapeutic proteins, such as immunoglobulins, albumin, coagulation factors, and enzyme replacements. These derivatives are essential for treating immune deficiencies, bleeding disorders, and various chronic and acute conditions. Growth in this market is driven by increasing global demand for plasma-derived therapies, advances in fractionation technology, and the expansion of plasma collection infrastructure. As healthcare access improves worldwide and rare disease diagnosis rises, the plasma fractionation industry is set to continue growing steadily in the years ahead.
According to Fortune Business Insights, the global plasma fractionation market was valued at USD 37.31 billion in 2024 and is projected to grow from USD 40.27 billion in 2025 to USD 72.45 billion by 2032, exhibiting a CAGR of 8.8% during the forecast period. In 2024, North America dominated the plasma fractionation market with a market share of 56.18%.
In July 2024, Kedrion S.p.A. announced a long-term commercialization and distribution agreement for Yimmugo—a key immunoglobulin therapy—in the U.S. through collaboration with Biotest AG. This strategic move underscores Kedrion's focus on expanding its product reach and bolstering its U.S. footprint.